{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:36:23Z","timestamp":1793450183835,"version":"4.5.0"},"reference-count":345,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021099","name":"Skye Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/V058266\/1"],"award-info":[{"award-number":["EP\/V058266\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009978","name":"Ernest Oppenheimer Memorial Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biotechadv.2026.108907","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T14:43:00Z","timestamp":1777214580000},"page":"108907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors"],"prefix":"10.1016","volume":"90","author":[{"given":"Sarah","family":"de la Mota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Suchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirthe","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Stibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Silva Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim A.","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biotechadv.2026.108907_bb0005","series-title":"A Piece of the COVID Vaccine Recipe","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2023.111015","article-title":"Potential health risks of mRNA-based vaccine therapy: a hypothesis","volume":"171","author":"Acevedo-Whitehouse","year":"2023","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2007.05.008","article-title":"Colloidally stable novel copolymeric system for gene delivery in complete growth media","volume":"121","author":"Agarwal","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR t cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/156652311796150372","article-title":"Adenoviral vector immunity: its implications and circumvention strategies","volume":"11","author":"Ahi","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0035","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European medicines agency review of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1039\/D1BM01454D","article-title":"Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)","volume":"10","author":"\u00c1lvarez-Benedicto","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joco.2018.01.006","article-title":"Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation","volume":"30","author":"Ameri","year":"2018","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0055","series-title":"Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform","author":"Andorko","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0060","series-title":"ApexOnco on In Vivo CAR-T","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0065","series-title":"Approved Cellular and Gene Therapy Products","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0080","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0090","series-title":"Adherent Versus Suspension Based Platforms: What Is the Near Future of Viral Vector Manufacturing?","author":"Baghirzade","year":"2022"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2019.11.011","article-title":"Production of lentiviral vectors using suspension cells grown in serum-free media","volume":"17","author":"Bauler","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0100","series-title":"FDAs Latest CGT Guidance Streamlines Path for In Vivo CAR-T Development","author":"Beaney","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0110","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood-2023-184312","article-title":"Development of novel lipid nanoparticles and virus-like particles for in vivo engineering of immune cells for targeted cancer therapy","volume":"142","author":"Beltran-Garcia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005641","article-title":"Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment","volume":"12","author":"Bender","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0120","author":"Bhandari"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0125","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0145","series-title":"BioSpace on Azelea Therapeutics","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0150","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0155","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0160","series-title":"Gene Drives on the Horizon","author":"Board on Life Sciences, Division on Earth and Life Studies, National Academies of Sciences Engineering and Medicine","year":"2016"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0165","author":"Bohonak"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/JVI.01865-08","article-title":"Insertional gene activation by lentiviral and gammaretroviral vectors","volume":"83","author":"Bokhoven","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0175","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00050","article-title":"Systemic gene delivery to the central nervous system using adeno-associated virus","volume":"7","author":"Bourdenx","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0190","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0195","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","article-title":"Early cost-effectiveness of onasemnogene Abeparvovec-xioi (zolgensma) and nusinersen (spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios","volume":"24","author":"Broekhoff","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0210","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: a review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0215","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618427","article-title":"Allogeneic CAR cell therapy\u2014more than a pipe dream","volume":"11","author":"Caldwell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0225","series-title":"An Inherent T Cell-Activating mRNA Delivery Platform for In Vivo CAR T Generation","author":"Cao","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0230","author":"Capra"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0240","author":"Catignol"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0245","author":"Cd, L.U.C.N., cell encoding ARSA gene"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0250","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0255","series-title":"Technology for In Vivo CAR T-Cell Therapy Advances","author":"Challener","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0260","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1021\/bc1000609","article-title":"Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape","volume":"21","author":"Chang","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1006\/mthe.2000.0219","article-title":"Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors","volume":"2","author":"Chao","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0270","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1039\/b718235j","article-title":"A microfluidic platform for integrated synthesis and dynamic light scattering measurement of block copolymer micelles","volume":"8","author":"Chastek","year":"2008","journal-title":"Lab Chip"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2020.08.011","article-title":"Rapid lentiviral vector producer cell line generation using a single DNA construct","volume":"19","author":"Chen","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0280","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0285","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/nar\/gkq922","article-title":"Amphiphilic block copolymers enhance the cellular uptake of DNA molecules through a facilitated plasma membrane transport","volume":"39","author":"Ch\u00e8vre","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BA20000022","article-title":"Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent","volume":"32","author":"Cho","year":"2000","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0295","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156652308786848021","article-title":"Mechanisms governing lentivirus integration site selection","volume":"8","author":"Ciuffi","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0310","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2020.107868","article-title":"Lentiviral vector bioprocess economics for cell and gene therapy commercialization","volume":"167","author":"Comisel","year":"2021","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0320","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0325","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.omtm.2020.12.005","article-title":"Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation","volume":"20","author":"Counsell","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0330","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1007\/s00253-023-12634-w","article-title":"Scalable manufacturing of gene-modified human mesenchymal stromal cells with microcarriers in spinner flasks","volume":"107","author":"Couto","year":"2023","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0335","article-title":"Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach","volume":"34","author":"Couto","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0340","series-title":"Umoja Biopharma\u2019s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-human Primate Study at the 8th CAR-TCR Summit","author":"Cross","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104337","article-title":"Long-term follow-up after authorization of gene therapy: leveraging real-world data","volume":"30","author":"de Haart","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0350","series-title":"Defining the Required Critical Quality Attributes (CQAs) and Phase Requirements for mRNA\/LNP Product Development and Manufacture","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0355","author":"Deladeriere"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.786174","article-title":"Immunotherapy and gene therapy: new challenges in the diagnosis and management of drug-induced liver injury","volume":"12","author":"Delire","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0365","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","article-title":"T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8","volume":"32","author":"Demircan","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0375","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0380","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0385","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6064\/2012\/694137","article-title":"Retroviral and lentiviral vectors for the induction of immunological tolerance","volume":"2012","author":"Dufait","year":"2012","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0395","author":"Dunleavy"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0400","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fphar.2018.00971","article-title":"Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers","volume":"9","author":"Durymanov","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0405","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/1078-0432.CCR-22-3232","article-title":"Enhancing CD19 chimeric antigen receptor T cells through memory-enriched T cells","volume":"29","author":"El Marabti","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0410","series-title":"Glybera","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0415","series-title":"Luxturna","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0420","author":"EMA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0425","series-title":"Libmeldy","author":"EMA","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.201700375","article-title":"State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery","volume":"2","author":"Evers","year":"2018","journal-title":"Small Methods"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0440","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-2836(02)01237-8","article-title":"Biophysical properties of human antibody variable domains","volume":"325","author":"Ewert","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0445","series-title":"In Vivo Delivery of CD3-Directed CD19-CAR Lentivectors Leads to the Generation of CAR-T and NK-Like (CAR-TaNK) Cells Capable of Complete Ablation of B Cells in the Blood, Bone Marrow, and Tissue in NSG-SGM3 CD34+ Humanized Mice","author":"EXUMA","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0450","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0455","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0460","author":"FDA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0465","series-title":"FDA Approval History","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0470","author":"FDA on CAR-T Follow-up"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0475","series-title":"FDA Safety & Availability (Biologics)","year":"2024"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0480","series-title":"FDA Investigating Serious Risk of T-Cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies","author":"FDA, T-cell Malignancy post CAR-T","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0485","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0490","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00939-20","article-title":"An essential membrane protein modulates the proteolysis of LpxC to control lipopolysaccharide synthesis in Escherichia coli","volume":"11","author":"Fivenson","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0495","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0500","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/hum.2019.248","article-title":"CD8-specific designed ankyrin repeat proteins improve selective gene delivery into human and primate t lymphocytes","volume":"31","author":"Frank","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0510","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.2c00346","article-title":"Modular adapters utilizing binders of different molecular types expand cell-targeting options for adenovirus gene delivery","volume":"33","author":"Freitag","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0515","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2023.02.012","article-title":"Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo","volume":"29","author":"Freitag","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0520","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/mt.2008.128","article-title":"Targeted cell entry of lentiviral vectors","volume":"16","author":"Funke","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0525","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hgtb.2012.194","article-title":"Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo","volume":"24","author":"Gabriel","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0530","series-title":"Two New Capture Options for Improved Purification of Large mRNA","author":"Gagnon","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0535","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0540","series-title":"Lilly Buys \u2018In Vivo\u2019 CAR-T Maker Orna, Extending Streak of Genetic Medicine Deals","author":"Gardner","year":"2026"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0545","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/bc700311n","article-title":"HER2 targeted polyplexes: the effect of polyplex composition and conjugation chemistry on in vitro and in vivo characteristics","volume":"19","author":"Germershaus","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0550","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0555","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0560","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0565","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0570","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.omtm.2021.02.010","article-title":"Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies","volume":"20","author":"Gimpel","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0575","series-title":"GlobeNewswire on Azalea Therapeutics","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0580","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0585","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1089\/hum.2017.172","article-title":"Small but increasingly mighty: latest advances in AAV vector research, design, and evolution","volume":"28","author":"Grimm","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0590","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","article-title":"Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening","volume":"316","author":"Guimaraes","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0595","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/v12091016","article-title":"Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy","volume":"12","author":"Gutierrez-Guerrero","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0600","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0605","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10982-y","article-title":"Physicochemical stability and transfection efficiency of cationic amphiphilic copolymer\/pDNA polyplexes for spinal cord injury repair","volume":"7","author":"Gwak","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0615","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ymthe.2017.01.024","article-title":"Polyplex evolution: understanding biology, optimizing performance","volume":"25","author":"Hall","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0620","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0625","series-title":"Non-Viral Gene Delivery to T Cells with Lipofectamine LTX","author":"Harris","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0630","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0635","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1128\/JVI.73.7.6141-6146.1999","article-title":"Frequency and stability of chromosomal integration of adenovirus vectors","volume":"73","author":"Harui","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0645","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/JVI.77.4.2768-2774.2003","article-title":"Characterization of tissue tropism determinants of adeno-associated virus type 1","volume":"77","author":"Hauck","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0650","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0655","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1007\/s00253-023-12689-9","article-title":"Production of retroviral vectors in continuous high cell density culture","volume":"107","author":"Hein","year":"2023","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0660","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biomaterials.2016.11.052","article-title":"Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity","volume":"118","author":"Hess","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0665","series-title":"Unlocking Precision Gene Therapy: Harnessing AAV Tropism with Nanobody Swapping at Capsid Hotspots","author":"Hoffmann","year":"2024"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0670","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10555-024-10185-8","article-title":"In vivo manufacture and manipulation of CAR-T cells for better druggability","volume":"43","author":"Hou","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0675","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0680","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0685","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","article-title":"Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis","volume":"100","author":"Hu","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002737","article-title":"Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells","volume":"9","author":"Huckaby","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0695","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0700","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105358","article-title":"Polyplexes for gene and nucleic acid delivery: progress and bottlenecks","volume":"150","author":"Ita","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0710","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0715","article-title":"Advanced microfluidic techniques for the preparation of solid lipid nanoparticles: innovations and biomedical applications","volume":"10","author":"Javid-Naderi","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0720","first-page":"25","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform FasT CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0725","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i1.10","article-title":"Pluronic? Block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers","volume":"19","author":"Kabanov","year":"2002","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98657-7","article-title":"A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system","volume":"11","author":"Kalidasan","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0740","doi-asserted-by":"crossref","first-page":"19244","DOI":"10.1021\/acsnano.1c04862","article-title":"Simultaneous, single-particle measurements of size and loading give insights into the structure of drug-delivery nanoparticles","volume":"15","author":"Kamanzi","year":"2021","journal-title":"ACS Nano"},{"issue":"Suppl. 1","key":"10.1016\/j.biotechadv.2026.108907_bb0745","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0750","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of \u03b6-deficient CARs into the CD3\u03b6 gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0755","doi-asserted-by":"crossref","first-page":"10645","DOI":"10.1002\/anie.201604067","article-title":"A precise chemical strategy to alter the receptor specificity of the adeno-associated virus","volume":"55","author":"Kelemen","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0760","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1182\/blood.V90.11.4638","article-title":"Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons","volume":"90","author":"Kiem","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0765","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0770","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10611860902767232","article-title":"Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes","volume":"17","author":"Kim","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0775","series-title":"Viral Vector Characterization: A Look at Analytical Tools","author":"King","year":"2018"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0780","series-title":"Process-Cost Modelling for Producing 100 Million COVID19 mRNA Vaccine Doses Per Year at Injectable Medicines Manufacturing Sites","author":"Kis","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0785","series-title":"How to Make Enough Vaccine for the World in One Year","author":"Kis","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0790","series-title":"Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand - Supplementary Informtion (SI) Document","author":"Kis","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0795","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/bit.28413","article-title":"Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines","volume":"120","author":"Klimpel","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0800","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1021\/mp900016q","article-title":"Delivery of polyethylenimine\/DNA complexes assembled in a microfluidics device","volume":"6","author":"Koh","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0805","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1242\/dev.115253","article-title":"Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant","volume":"142","author":"Kotterman","year":"2015","journal-title":"Development"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0810","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.omtm.2017.11.006","article-title":"Engineering PTEN-L for cell-mediated delivery","volume":"9","author":"Lavictoire","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0815","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0820","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11095-006-9136-9","article-title":"Thiolated chitosan\/DNA nanocomplexes exhibit enhanced and sustained gene delivery","volume":"24","author":"Lee","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0825","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-associated virus (AAV) vectors: rational design strategies for capsid engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0830","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216519","article-title":"Adenoviral gene therapy vectors in clinical use-basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety","volume":"24","author":"Leikas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","author":"Lemgart","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0845","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/mt.2012.96","article-title":"Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells","volume":"20","author":"L\u00e9vy","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0850","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0855","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162939","article-title":"In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies","volume":"7","author":"Li","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0860","first-page":"1","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0865","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0870","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41467-025-67239-w","article-title":"Efficient high-precision transgene knock-in by recombinases (red\u03b1\/\u03b2)-enhanced DNA integration-CRISPR-Cas9 (RED-CRISPR)","volume":"17","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0875","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","article-title":"Adeno-associated virus serotypes for gene therapeutics","volume":"24","author":"Lisowski","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0880","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/s41467-025-59501-y","article-title":"Structure-guided design of endosomolytic chloroquine-like lipid nanoparticles for mRNA delivery and genome editing","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0885","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.omtm.2021.03.015","article-title":"Efficient lentiviral transduction method to gene modify cord blood CD8+ t cells for cancer therapy applications","volume":"21","author":"Lo Presti","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0890","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3893","article-title":"Identification of liver-specific enhancer\u2013promoter activity in the 3\u2032 untranslated region of the wild-type AAV2 genome","volume":"49","author":"Logan","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0895","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/hum.2013.210","article-title":"Full-length dystrophin reconstitution with adeno-associated viral vectors","volume":"25","author":"Lostal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0900","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jgm.896","article-title":"Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector","volume":"8","author":"Lu","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0905","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0910","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0915","series-title":"Regular and Young Investigator Award Abstracts. Presented at the SITC 37th Annual Meeting (SITC 2022) Abstracts","article-title":"1222 In situ CAR therapy using oRNA\u2122 lipid nanoparticles regresses tumors in mice","author":"Mabry","year":"2022"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0920","author":"Mack"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0925","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0930","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","article-title":"Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery","volume":"344","author":"Maeki","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0935","article-title":"Mass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices","volume":"31","author":"Maeki","year":"2023","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0940","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0945","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pharmaceutics12111051","article-title":"Large-scale production of lentiviral vectors: current perspectives and challenges","volume":"12","author":"Mart\u00ednez-Molina","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0950","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1016\/j.xphs.2021.06.031","article-title":"Comprehensive size distribution and composition analysis of adeno-associated virus vector by multiwavelength sedimentation velocity analytical ultracentrifugation","volume":"110","author":"Maruno","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0955","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.1021\/acsanm.2c00886","article-title":"Microfluidic device-enabled mass production of lipid-based nanoparticles for applications in nanomedicine and cosmetics","volume":"5","author":"Matsuura-Sawada","year":"2022","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0960","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14834","article-title":"Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system","volume":"8","author":"Maunder","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-82599-1","article-title":"Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering","volume":"11","author":"McIntosh","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0970","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0980","article-title":"Nanoplatforms for mRNA therapeutics","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther. (Weinh.)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb0985","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/ijms26073119","article-title":"In vivo engineered CAR-T cell therapy: lessons built from COVID-19 mRNA vaccines","volume":"26","author":"Meng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0990","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bej.2015.09.005","article-title":"Viral vectors for gene therapy and gene modification approaches","volume":"108","author":"Merten","year":"2016","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb0995","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1000","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2021.09.014","article-title":"Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8","volume":"23","author":"Michels","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1005","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1020","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/JVI.03371-13","article-title":"Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans","volume":"88","author":"Mietzsch","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8922-5_5","article-title":"Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for cancer immunotherapy","volume":"1895","author":"Minagawa","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1040","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/v13081471","article-title":"Efficient pseudotyping of different retroviral vectors using a novel, codon-optimized gene for chimeric GALV envelope","volume":"13","author":"Mirow","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1045","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.3390\/cimb45100486","article-title":"Targeted delivery of chimeric antigen receptor into T cells via CRISPR-mediated homology-directed repair with a dual-AAV6 transduction system","volume":"45","author":"Mo\u00e7o","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1050","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3627","article-title":"Enhancement of adeno-associated virus serotype 6 transduction into T cells with cell-penetrating peptides","volume":"26","author":"Mo\u00e7o","year":"2024","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1055","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","article-title":"Pro-inflammatory concerns with lipid nanoparticles","volume":"30","author":"Moghimi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1060","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"131","article-title":"Lymphodepleting conditioning regimens","author":"Mohty","year":"2022"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Monta\u00f1o-Samaniego","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.snb.2021.130538","article-title":"An automated low-cost modular hardware and software platform for versatile programmable microfluidic device testing and development","volume":"346","author":"Morbioli","year":"2021","journal-title":"Sensors Actuators B Chem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1075","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1080","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00900-18","article-title":"Characterization of antibody interactions with the G protein of vesicular stomatitis virus Indiana strain and other vesiculovirus G proteins","volume":"92","author":"Munis","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1085","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.17576\/jsm-2017-4610-21","article-title":"Overcoming the challenge of transduction of human T-cells with chimeric antigen receptor (CAR) specific for ERBB2 antigen","volume":"46","author":"Munisvaradass","year":"2017","journal-title":"Sains Malays."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/138920210790886871","article-title":"DNA transposons: nature and applications in genomics","volume":"11","author":"Munoz-Lopez","year":"2010","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1095","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1100","first-page":"97","article-title":"Use of adeno-associated virus as a general transduction vector for mammalian cells","volume":"158","author":"Muzyczka","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1105","series-title":"Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors","author":"Myeloidtx","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"Nadeau","year":"2003","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nbt1060","article-title":"Rescue and propagation of fully retargeted oncolytic measles viruses","volume":"23","author":"Nakamura","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1125","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1038\/s41467-022-32281-5","article-title":"Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo","volume":"13","author":"Ni","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1135","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2014.08.028","article-title":"Decationized polyplexes as stable and safe carrier systems for improved biodistribution in systemic gene therapy","volume":"195","author":"Novo","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/17425247.2015.988136","article-title":"Decationized polyplexes for gene delivery","volume":"12","author":"Novo","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acssynbio.2c00609","article-title":"Low resource integrated platform for production and analysis of capped mRNA","volume":"12","author":"Nwokeoji","year":"2023","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1150","series-title":"NxGen Technology for Scaling Nanoparticle Production","year":"2026"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus","volume":"12","author":"Ono","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1165","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1170","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1175","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1128\/JVI.02032-12","article-title":"Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo","volume":"87","author":"Palomares","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1180","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.gt.3302895","article-title":"Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo","volume":"14","author":"Palomeque","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1185","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1195","series-title":"Exclusive: Inside the Facilities Making the World\u2019s Most Prevalent COVID-19 Vaccine","author":"Park","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113368","article-title":"Anticancer nanotherapeutics in clinical trials: the work behind clinical translation of nanomedicine","volume":"23","author":"Parodi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1210","series-title":"Evolution of Viral Vector Analytics for Gene Therapy Manufacturing","author":"Patrick Moran","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1220","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1225","series-title":"Fourth Boy Dies in Trial of Astellas Gene Therapy Candidate","author":"Philippidis","year":"2021"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.omtm.2019.09.001","article-title":"A muscle hybrid promoter as a novel tool for gene therapy","volume":"15","author":"Piekarowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1235","series-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2023","article-title":"In vivo delivery of novel CD89 fusion receptor to myeloid cells by mRNA activates anti-tumor immunity","author":"Prod\u2019homme","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1039\/D2LC00744D","article-title":"A new microfluidic platform for the highly reproducible preparation of non-viral gene delivery complexes","volume":"23","author":"Protopapa","year":"2022","journal-title":"Lab Chip"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1245","article-title":"Promoter choice: who should drive the CAR in T cells?","volume":"15","author":"Rad","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1250","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes","volume":"32","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1260","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41551-023-01013-5","article-title":"A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor","volume":"7","author":"Reichenbach","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1265","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2004.10.014","article-title":"Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells","volume":"11","author":"Relander","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1270","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/pr6100188","article-title":"Non-viral transfection of human T lymphocytes","volume":"6","author":"Riedl","year":"2018","journal-title":"Processes (Basel)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1275","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/pharmaceutics12111095","article-title":"Manufacturing considerations for the development of lipid nanoparticles using microfluidics","volume":"12","author":"Roces","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1280","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/bit.28216","article-title":"Maximizing mRNA vaccine production with Bayesian optimization","volume":"119","author":"Rosa","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1295","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","article-title":"Landscape of cancer cell therapies: trends and real-world data","volume":"21","author":"Saez-Iba\u00f1ez","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1305","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1310","doi-asserted-by":"crossref","DOI":"10.1002\/amp2.10158","article-title":"Characterization of key manufacturing uncertainties in next generation therapeutics and vaccines across scales","volume":"5","author":"Sarkis","year":"2023","journal-title":"J. Adv. Manuf. Process."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1315","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.ymthe.2020.05.019","article-title":"Efficient nuclease-directed integration of lentivirus vectors into the human ribosomal DNA locus","volume":"28","author":"Schenkwein","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1320","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1325","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1330","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/pr9111874","article-title":"Fast and flexible mRNA vaccine manufacturing as a solution to pandemic situations by adopting chemical engineering good practice\u2014continuous autonomous operation in stainless steel equipment concepts","volume":"9","author":"Schmidt","year":"2021","journal-title":"Processes (Basel)"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"MRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-3155-12-5","article-title":"Engineered nanoparticles interacting with cells: size matters","volume":"12","author":"Shang","year":"2014","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1345","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1350","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1355","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/bm400342f","article-title":"Influence of histidine incorporation on buffer capacity and gene transfection efficiency of HPMA-co-oligolysine brush polymers","volume":"14","author":"Shi","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1360","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1365","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1370","series-title":"Expansion of Human Mesenchymal Stem\/Stromal Cells (hMSCs) in Bioreactors Using Microcarriers: Lessons Learnt and What the Future Holds","volume":"45","author":"Silva Couto","year":"2020"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1375","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10529-023-03369-9","article-title":"Understanding the impact of bioactive coating materials for human mesenchymal stromal cells and implications for manufacturing","volume":"45","author":"Silva Couto","year":"2023","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jcyt.2024.05.020","article-title":"Biological differences between adult and perinatal human mesenchymal stromal cells and their impact on the manufacturing processes","volume":"26","author":"Silva Couto","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1385","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jcyt.2024.06.011","article-title":"Generating suspension-adapted human mesenchymal stromal cells (S-hMSCs) for the scalable manufacture of extracellular vesicles","volume":"26","author":"Silva Couto","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1390","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70114","article-title":"Impact of serum\/Xeno-free medium and cytokine supplementation on CAR-T cell therapy manufacturing in stirred tank bioreactors","volume":"20","author":"Silva Couto","year":"2025","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1395","series-title":"Kelonia Therapeutics Presents Research Highlighting Potential of iGPS\u2122 In Vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of all Multiple Myeloma Patients","author":"Silverstein","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1400","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jnt5030007","article-title":"Anti-poly(ethylene glycol) (PEG) antibodies: from where are we coming and where are we going","volume":"5","author":"Simberg","year":"2024","journal-title":"J. Nanotheranostics"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1405","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/exd.13678","article-title":"The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma","volume":"27","author":"Simon","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1410","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1415","series-title":"Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for its First-In-Class in Vivo CAR Therapeutic for B Cell Malignancies","author":"Smitherman","year":"2024"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1420","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/acsnano.4c18636","article-title":"Ionizable lipids with optimized linkers enable lung-specific, lipid nanoparticle-mediated mRNA delivery for treatment of metastatic lung tumors","volume":"19","author":"Somu Naidu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1425","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1430","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","article-title":"CRISPR\/Cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1435","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41467-025-67201-w","article-title":"Chemically-inducible CRISPR\/Cas9 circuits for ultra-high dynamic range gene perturbation","volume":"17","author":"Srinivasan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1440","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1445","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1450","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00249-023-01654-z","article-title":"Optimizing high-throughput viral vector characterization with density gradient equilibrium analytical ultracentrifugation","volume":"52","author":"Sternisha","year":"2023","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1455","article-title":"Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line","volume":"32","author":"Stibbs","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1460","article-title":"Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor","volume":"32","author":"Stibbs","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1465","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jgm.1129","article-title":"AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid","volume":"10","author":"Su","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1470","first-page":"301","article-title":"Lentiviral transduction of immune cells","volume":"415","author":"Swainson","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1480","series-title":"The Nobel Prize in Physiology or Medicine 2023","year":"2026"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1485","series-title":"The Sector Snapshot: August 2024","year":"2024"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1490","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1495","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.omtm.2020.08.005","article-title":"Rapid in-process monitoring of lentiviral vector particles by high-performance liquid chromatography","volume":"18","author":"Transfiguracion","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1500","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1510","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11095-007-9284-6","article-title":"Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery","volume":"24","author":"van Vlerken","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1515","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1520","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1525","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/d41573-023-00002-2","article-title":"The landscape for lipid-nanoparticle-based genomic medicines","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1530","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2018-0085","article-title":"A dozen years of clinical trials performing advanced cell therapy with perinatal cells","volume":"4","author":"Verter","year":"2018","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1535","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1021\/acs.jpcb.7b10795","article-title":"Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy","volume":"122","author":"Viger-Gravel","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1540","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1545","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/pharmaceutics15041053","article-title":"Use of microfluidics to prepare lipid-based nanocarriers","volume":"15","author":"Vogelaar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1550","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1182\/bloodadvances.2020002237","article-title":"Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients","volume":"4","author":"Vuckovic","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1555","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.gt.3302011","article-title":"Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain","volume":"10","author":"Wang","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1560","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1565","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","article-title":"Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1570","article-title":"Co-delivery of multiple RNAs via lipid nanoparticles enables precise gene editing of CAR-T cells","volume":"15","author":"Wang","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1575","doi-asserted-by":"crossref","DOI":"10.1038\/srep45329","article-title":"Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection","volume":"7","author":"Wassmer","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1580","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1585","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/mt.2013.26","article-title":"RNA-based vaccination: sending a strong message","volume":"21","author":"Weiner","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1590","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jmb.2007.11.046","article-title":"Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins","volume":"376","author":"Wetzel","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1595","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/hgtb.2017.096","article-title":"A guide to approaching regulatory considerations for lentiviral-mediated gene therapies","volume":"28","author":"White","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1600","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2021012349","article-title":"Expect the unexpected: piggyBac and lymphoma","volume":"138","author":"Wilson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1605","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jconrel.2022.12.008","article-title":"Engineering poly- and micelleplexes for nucleic acid delivery - a reflection on their endosomal escape","volume":"353","author":"Winkeljann","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1610","series-title":"Pharmaceutical Biotechnology","first-page":"323","article-title":"Gene therapy","author":"Wu","year":"2019"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1615","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1620","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jcyt.2017.12.007","article-title":"Toward precision manufacturing of immunogene T-cell therapies","volume":"20","author":"Xu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1625","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101266","article-title":"Adeno-associated virus perfusion enhanced expression: a commercially scalable, high titer, high quality producer cell line process","volume":"32","author":"Xue","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1630","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","article-title":"Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery","volume":"20","author":"Xue","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1635","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jconrel.2023.06.012","article-title":"Calcium carbonate nanoparticles tumor delivery for combined chemo-photodynamic therapy: comparison of local and systemic administration","volume":"359","author":"Yakubova","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1640","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1720542115","article-title":"Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles","volume":"115","author":"Yanez Arteta","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1645","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1650","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1655","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1660","article-title":"Adenovirus serotype 5 vectors with tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1665","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.colsurfb.2017.10.044","article-title":"Modification of porous PLGA microspheres by poly-l-lysine for use as tissue engineering scaffolds","volume":"161","author":"Yuan","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1670","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1675","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jgm.2719","article-title":"Efficacy and mechanism of poloxamine-assisted polyplex transfection","volume":"15","author":"Zhang","year":"2013","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1680","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1685","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1690","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1695","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/1759-7714.13947","article-title":"Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: a case report","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1700","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1705","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fphar.2017.00510","article-title":"Immune activities of polycationic vectors for gene delivery","volume":"8","author":"Zhao","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1710","first-page":"205","article-title":"Evaluation of promoters for use in tissue-specific gene delivery","volume":"434","author":"Zheng","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1715","series-title":"Lipid Nanoparticle Topology Regulates Endosomal Escape and Delivery of RNA to the Cytoplasm","author":"Zheng","year":"2022"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1720","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.mt.6300170","article-title":"A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis","volume":"15","author":"Zhong","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1725","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","article-title":"Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression","volume":"381","author":"Zhong","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1730","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1735","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2012-02-412973","article-title":"T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biotechadv.2026.108907_bb1740","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","article-title":"Exclusive transduction of human CD4+ t cells upon systemic delivery of CD4-targeted lentiviral vectors","volume":"195","author":"Zhou","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108907_bb1745","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Control. Release"}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:04:36Z","timestamp":1784534676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975026001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":345,"alternative-id":["S0734975026001138"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108907","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108907"}}